Israel’s DreaMed (see here previously) has now received US FDA approval for use with Type 2 diabetes sufferers as well as Type 1. It will relieve the strain on endocrinologist who each have on average some 46,000 patients.
https://www.timesofisrael.com/spotlight/israeli-startup-offers-hope-in-global-diabetes-crisis/